Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Shellito

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
International Journal of Colorectal Disease|October 3, 2009
Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgeryLiliana Bordeianou, Hiroko Kunitake, Paul Shellito, et al.
Surgical Endoscopy|August 13, 2015
Transanal endoscopic resection with peritoneal entry: a word of cautionGeorge Molina, Liliana Bordeianou, Paul Shellito, et al.
Diseases of the Colon and Rectum|June 3, 2006
Practice parameters for sigmoid diverticulitisJanice Rafferty, Paul Shellito, Neil H Hyman, et al.
International Journal of Colorectal Disease|September 27, 2012
Does preoperative total parenteral nutrition in patients with ulcerative colitis produce better outcomes?Harry Salinas, Abdulmentin Dursun, Ioannis Konstantinidis, et al.
Archives of Surgery (Chicago, Ill. : 1960)|May 18, 2011
Determining the need for radical surgery in patients with T1 rectal cancerHarry M Salinas, Abdulmetin Dursun, Coen L Klos, et al.
Inflammatory Bowel Diseases|September 18, 2014
Natural history of perianal Crohn's disease after fecal diversionJenny Sauk, Deanna Nguyen, Vijay Yajnik, et al.
Diseases of the Colon and Rectum|June 4, 2005
Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised)Mark H Whiteford, John Kilkenny, Neil Hyman, et al.
The Oncologist|May 21, 2010
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancerDan G Duda, Christopher G Willett, Marek Ancukiewicz, et al.
Diseases of the Colon and Rectum|January 20, 2005
Practice parameters for the management of anal fissures (revised)Charles Orsay, Jan Rakinic, W Brian Perry, et al.
Cancer Research|October 15, 2009
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerLei Xu, Dan G Duda, Emmanuelle di Tomaso, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
International Journal of Colorectal Disease|October 3, 2009
Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgeryLiliana Bordeianou, Hiroko Kunitake, Paul Shellito, et al.
Surgical Endoscopy|August 13, 2015
Transanal endoscopic resection with peritoneal entry: a word of cautionGeorge Molina, Liliana Bordeianou, Paul Shellito, et al.
Diseases of the Colon and Rectum|June 3, 2006
Practice parameters for sigmoid diverticulitisJanice Rafferty, Paul Shellito, Neil H Hyman, et al.
International Journal of Colorectal Disease|September 27, 2012
Does preoperative total parenteral nutrition in patients with ulcerative colitis produce better outcomes?Harry Salinas, Abdulmentin Dursun, Ioannis Konstantinidis, et al.
Archives of Surgery (Chicago, Ill. : 1960)|May 18, 2011
Determining the need for radical surgery in patients with T1 rectal cancerHarry M Salinas, Abdulmetin Dursun, Coen L Klos, et al.
Inflammatory Bowel Diseases|September 18, 2014
Natural history of perianal Crohn's disease after fecal diversionJenny Sauk, Deanna Nguyen, Vijay Yajnik, et al.
Diseases of the Colon and Rectum|June 4, 2005
Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised)Mark H Whiteford, John Kilkenny, Neil Hyman, et al.
The Oncologist|May 21, 2010
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancerDan G Duda, Christopher G Willett, Marek Ancukiewicz, et al.
Diseases of the Colon and Rectum|January 20, 2005
Practice parameters for the management of anal fissures (revised)Charles Orsay, Jan Rakinic, W Brian Perry, et al.
Cancer Research|October 15, 2009
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerLei Xu, Dan G Duda, Emmanuelle di Tomaso, et al.
Pageof 2